Pfizer is backing Caribou Biosciences with a $25 million equity investment, money the genome editing company will pour into its allogeneic CAR-T cell therapy for multiple myeloma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,